Amgen stock heads into the open after a 1.34 percent drop

At the close on September 11, 2026, Amgen stock finished at USD 377.35 on Nasdaq after a 1.34 percent decline, moving about 15 percent below its 52-week high as the S&P 500 gained roughly 0.9 percent the same day.

Amgen stock closed at USD 377.35 on Nasdaq on September 11, 2026, down 1.34 percent from the prior session. Compared with its recent peak, Amgen stock traded about 15 percent below its 52-week high at that close while the broader US equity market advanced on the same day.

September 11, 2026 in numbers

Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) ended trading on September 11, 2026 at USD 377.35 on its primary US venue, according to exchange data compiled by Investing.com and Nasdaq. Intraday, the shares traded between a high of USD 386.99 and a low of USD 377.22, with an open at USD 386.14, keeping the final price close to the session low and marking a clear step down from the previous day. Per Nasdaq data summarized by MarketBeat, the move left Amgen stock about 15 percent below its 52-week high and implied a market capitalization of roughly USD 204.01 billion at the close, with trading volume around 759,306 shares on September 11, 2026.Ad-hoc-news reported that the downturn followed a fresh HSBC rating change to Hold from Buy on Amgen, with the bank cutting its price target to 425 dollars from 445 dollars and arguing that the shares had re-rated on strong execution and now trade close to fair value.

According to the Amgen price history on Investing.com, the 1.34 percent decline on September 11, 2026 contrasted with gains in major US indices that day, as the S&P 500 and Nasdaq Composite both advanced by around 0.9 percent. This performance underscored that stock-specific factors, notably the HSBC downgrade and updated view on Amgen’s obesity candidate MariTide, weighed on the shares even as the broader healthcare and equity benchmarks moved higher.Investing.com and a weekly analyst wrap on Investing.com highlighted the HSBC move among notable healthcare calls.

Today’s drivers to watch

As of today, September 14, 2026, no new Amgen-specific earnings release or major corporate event is scheduled to hit ahead of the US opening bell in the available calendars and news reports, so traders remain focused on the implications of last week’s HSBC downgrade and the timeline for upcoming trial readouts such as the MariTide obesity program mentioned in the analyst note.Investing.com Meanwhile, broader market sentiment today will be shaped by macroeconomic data and policy signals flagged in economic calendars on Investing.com, which could influence rate-sensitive healthcare stocks like Amgen through moves in yields and risk appetite.